Skip to content

Dr. Gearóid Tuohy

Results from a cross sectional study of XLRP patients suggest that several healthcare systems require early diagnosis and effective management of patients.

Researchers at Janssen Pharmaceuticals N.V. and the ERN-EYE Network at the Center for Retinitis Pigmentosa of Veneto Region, Camposampiero Hospital, Padua, Italy, have reported results… Read More »Results from a cross sectional study of XLRP patients suggest that several healthcare systems require early diagnosis and effective management of patients.

Kioro Pharmaceuticals (NASDAQ: KPRX) has announced Orphan Medicinal Product Designation for KIO-310, for the treatment of non-syndromic rod-dominant retinal dystrophies.    

Kiora Pharmaceuticals (NASDAQ: KPRX) have announced the receipt of Orphan Medicinal Product Designation from the European Medicines Agency (EMA) for the treatment of IRDs, including… Read More »Kioro Pharmaceuticals (NASDAQ: KPRX) has announced Orphan Medicinal Product Designation for KIO-310, for the treatment of non-syndromic rod-dominant retinal dystrophies.    

A first in-depth retrospective longitudinal study of Usher syndrome on USH1D, providing key natural history, image data and clinical features.

Researchers at UCL Institute of Ophthalmology, University College London, and Moorfields Eye Hospital, have reported a detailed natural history, retinal imaging dataset and clinical features… Read More »A first in-depth retrospective longitudinal study of Usher syndrome on USH1D, providing key natural history, image data and clinical features.

Book Review of Low Vision-Principles and Management, 1st edition (Elsevier); by Christine Dickinson, Ana Hernandez Trillo and Michael Crossland

According to the Royal College of Ophthalmologists, the term of “low vision” is not defined in UK legislation however, the UK Low Vision Services Consensus… Read More »Book Review of Low Vision-Principles and Management, 1st edition (Elsevier); by Christine Dickinson, Ana Hernandez Trillo and Michael Crossland

Genentech (Roche Group) announce that FDA has approved the introduction of Susimvo (ranibizumab injection, ocular implant) for wet age-related macular degeneration. 

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), have announced the reintroduction of “Susvimo” (ranibizumab injection) 100 mg/mL for intravitreal use… Read More »Genentech (Roche Group) announce that FDA has approved the introduction of Susimvo (ranibizumab injection, ocular implant) for wet age-related macular degeneration. 

Early warning signs of diabetic retinopathy (DR) in clinics shows exponentially increases in prevalence on type 1 DR and type 2 DR.

Researchers at the Center for Ophthalmic Bioinformatics Research at the Cole Eye Institute, Cleveland, Ohio, have reported that the prevalence of diabetic retinopathy (DR) changed… Read More »Early warning signs of diabetic retinopathy (DR) in clinics shows exponentially increases in prevalence on type 1 DR and type 2 DR.

AAV treatment or surgical issues on chorioretinal atrophy? Researchers report on a study on potential adverse events in a gene therapy treatment.

Researchers based at the Nuffield Department of Clinical Neurosciences, The John Radcliffe Hospital, University of Oxford, have reported a new study on the mechanism of… Read More »AAV treatment or surgical issues on chorioretinal atrophy? Researchers report on a study on potential adverse events in a gene therapy treatment.